Top Stories Monday, December 19, 2016 Harbour BioMed has bought an Atlas Venture-backed antibody player to further its ambition to build a pipeline of immuno-oncology programs. The deal sees Chinese VCs teaming with Big Pharma veterans to gain control of transgenic mouse platforms developed and commercialized in Cambridge, Massachusetts, and Rotterdam, the Netherlands. Monday, December 19, 2016 Canadian biotech Northern Biologics has signed a “transformative” merger deal with Spain’s Mosaic Biomedicals as the new player looks to become a global cancer company, eyeing 2017 in-human testing for its lead candidate. Monday, December 19, 2016 A spinout from the Wellcome Trust Sanger Institute’s microbiome research group has raised $10 million to advance live bacteriotherapy programs. The startup, Microbiotica, is helmed by a former GlaxoSmithKline executive and built on years of work to sequence the genomes of the thousands of bacteria that inhabit the guts of humans. Monday, December 19, 2016 Purdue has signed a new deal with Japanese drugmaker Shionogi that will see the pair work together to sell in the U.S. the latter’s opioid-induced constipation candidate Symproic (naldemedine). Monday, December 19, 2016 MicroPort Scientific has invested $15 million in Lombard Medical as part of a deal that gives it rights to stent grafts in China and Brazil. The pact gives Lombard a partner capable of commercializing its Aorfix and Altura stent grafts in key global markets, plus an infusion of capital and component supply pact. Monday, December 19, 2016 Hoping to gain some stability, Dutch gene therapy company UniQure has awarded the CEO role to Matthew Kapusta, who took over as interim leader in September, and who now becomes the company's third CEO in a year. | | | German biotech Medigene told Reuters it has been "drawing more interest from prospective alliance partners" for its tech after a Bluebird Bio deal. Reuters story The EMA said it is working on "tailored scientific advice" to help support step-by-step development of new biosimilars for biopharmas. Statement Vivo Capital and ZQ Capital signed a pact to buy out medical device company Angiotech Pharmaceuticals. Release | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. | 
